CN104623005B - The new application that the heart can relax - Google Patents
The new application that the heart can relax Download PDFInfo
- Publication number
- CN104623005B CN104623005B CN201410628529.8A CN201410628529A CN104623005B CN 104623005 B CN104623005 B CN 104623005B CN 201410628529 A CN201410628529 A CN 201410628529A CN 104623005 B CN104623005 B CN 104623005B
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- ginseng
- preparation
- pseudo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention provides purposes of the composition matched as follows in the medicine for preparing treatment cholestatic hepatitis；Described pharmaceutical composition is the preparation being prepared by the bulk pharmaceutical chemicals of following weight proportion：350~400 parts of hawthorn, 350~400 parts of Radix Salviae Miltiorrhizae, 350~400 parts of pueraria lobata, 20~30 parts of pseudo-ginseng, 20~30 parts of the banksia rose.Present invention research finds that the heart class medicine that can relax has cholestasis good therapeutic effect, and new selection is provided for clinical application.
Description
Technical field
The present invention relates to the new application that the heart can relax.
Background technology
Cholestasis type hepatitis is a kind of clinical syndrome, is common in INFANT HEPATITIS SYNDROME, hereditary metabolic disorders, original
In the diseases such as hair property biliary cirrhosis, sclerosing cholangitis, if effectively treatment not in time, after hepatic sclerosis etc. will be caused serious
Fruit.The common drug of clinical treatment cholestasis includes urso and cortin, but its curative effect is still dissatisfied.
The heart, which can relax, to be refined and is formed by Radix Salviae Miltiorrhizae, pueraria lobata, the banksia rose, pseudo-ginseng, hawthorn traditional Chinese medicine of the five flavours.Standard number：WS3-B-2856-
98, function is with curing mainly：Promoting blood circulation and removing blood stasis, promoting qi circulation and relieving pain.For uncomfortable in chest, angina pectoris caused by qi stagnation and blood stasis type coronary heart disease, hypertension,
The disease such as dizzy, headache, neck pain and arrhythmia cordis, hyperlipidemia.There are document report Xin Ke Shu ' tablet for treating coronary heart disease joint Silybin Capsules to control
Fatty liver disease is treated, there is good result (Li Weixiong, etc., Xin Ke Shu ' tablet for treating coronary heart disease joint Silybin Capsules treatment fatty liver disease, base
Layer medicine forum the 35th phase of volume 17 in December, 2013)
The content of the invention
It is an object of the invention to provide the new application that the heart can relax.
The present invention provides purposes of the composition matched as follows in the medicine for preparing treatment cholestatic hepatitis；The medicine
Compositions are the preparations being prepared by the bulk pharmaceutical chemicals of following weight proportion：
350~400 parts of hawthorn, 350~400 parts of Radix Salviae Miltiorrhizae, 350~400 parts of pueraria lobata, 20~30 parts of pseudo-ginseng, the banksia rose 20~30
Part.
Further, the medicine is the medicine for treating acute viral cholestatic hepatitis.
Further, the medicine is total bilirubin (TB), the bilirubin direct for reducing acute viral cholestatic hepatitis patient
(DB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase (GGT), total courage
The medicine of juice acid (TBA).
Further, the composition is the preparation being prepared by the bulk pharmaceutical chemicals of following weight proportion：
375 parts of hawthorn, 375 parts of Radix Salviae Miltiorrhizae, 375 parts of pueraria lobata, 25 parts of pseudo-ginseng, 25 parts of the banksia rose.
Wherein, the composition is water using the medicinal powder of bulk pharmaceutical chemicals or/and bulk pharmaceutical chemicals or/and ethanol extract as activity
Component, plus the preparation that pharmaceutically common auxiliary material is prepared.
Further, the preparation method of the active ingredient is as follows：Pseudo-ginseng, the banksia rose is taken to be ground into fine powder；Hawthorn, pueraria lobata add
After 60% ethanol temperature is soaked 30 minutes, heating and refluxing extraction is secondary, for the first time 2.5 it is small when, second 2 it is small when, merge alcohol extract, subtract
Receipts ethanol is pushed back, is concentrated into relative density 1.35 (20 DEG C)；Radix Salviae Miltiorrhizae add water to cook it is secondary, for the first time 2 it is small when, second 1.5 is small
When, collecting decoction filters, and filtrate is concentrated into relative density 1.35 (20 DEG C)；Above-mentioned two kinds of thick pastes dry, pulverize at 80 DEG C
Mixed into fine powder and pseudo-ginseng, banksia rose fine powder, up to active ingredient.
Wherein, the preparation is oral formulations.
The present invention is made the animal model of acute viral cholestatic hepatitis of α-α-naphthyl isothiocyanate (ANIT), can to inquire into the heart
Therapeutic effect and the mechanism relaxed to acute viral cholestatic hepatitis.Research finds, the heart class medicine that can relax has very cholestasis
Good therapeutic effect, new selection is provided for clinical application.
Embodiment
1 hair of test example inhales the test of pesticide effectiveness of drug therapy cholestatic hepatitis
1st, experimental animal
Cleaning grade SD rats, 180~220g of weight, is provided, experimental animal is closed by Chengdu up to large bio tech ltd
Lattice card number：scxkc(111)2008-24.
2nd, experiment equipment
Electronic balance (Beijing Sai Duolisi balances Co., Ltd, model BS-200S-WEI)；
Centrifuge (flying pigeon board, model：LXJ-ⅡB)；
Numerical control ultrasonic cleaner (Kunshan Ultrasonic Instruments Co., Ltd., model：KQ-500DB)；
High-precision electronic weight calculation claims (Foochow Chen Electronics Co., Ltd.s, model：AWH-30KC)；
Rotary Evaporators, condenser pipe, iron stand, round-bottomed flask (1000ml, 2000ml)；
Other：EP pipes (5ml, 10ml), beaker, graduated cylinder, conical flask, pan paper, operation sewing needle, operation suture thread, glass
Glass rod, cotton swab, gastric perfusion needle, syringe, constant temperature water bath apparatus, rat fixed plate, syringe, needle holder, tweezers number handle, size hand
It is appropriate etc. that art cuts several handles, rubber band；
Chloraldurate (Chengdu Ke Long chemical reagents factory, product batch number：20100920, specification：500g)；
Formaldehyde (Chengdu Ke Long chemical reagents factory, product batch number：20120320, specification：500ml)；
Absolute ethyl alcohol (Chengdu Ke Long chemical reagents factory, product batch number：20110820, specification：500ml)；
Sodium chloride injection (Kuming Nanjiang Pharmacy Co., Ltd, product batch number：D101211A2, specification：500ml：
4.5g)；Distilled water etc..
3rd, experimental drug
Urso (Ursofalk) (is purchased from German Dr.Falk Pharma GmbH pharmaceutical factories, lot number 0635240-01), and α-
α-naphthyl isothiocyanate (ANIT) is purchased from Sigma Co., USA.
Radix Salviae Miltiorrhizae (the natural pharmaceutcal corporation, Ltd in Sichuan Cologne, lot number 130401),
The banksia rose (the natural pharmaceutcal corporation, Ltd in Sichuan Cologne, lot number 130317),
Pueraria lobata (the natural pharmaceutcal corporation, Ltd in Sichuan Cologne, lot number 130214),
Pseudo-ginseng (the natural pharmaceutcal corporation, Ltd in Sichuan Cologne, lot number 130401),
Hawthorn (the natural pharmaceutcal corporation, Ltd in Sichuan Cologne, lot number 130428).
2nd, experimental method
1. medicine is prepared
Prescription：
Hawthorn 375g, Radix Salviae Miltiorrhizae 375g, pueraria lobata 375g, pseudo-ginseng 25g, banksia rose 25g.
Preparation method：
Pseudo-ginseng, the banksia rose is taken to be ground into fine powder；After hawthorn, pueraria lobata add 60% ethanol temperature to soak 30 minutes, heating and refluxing extraction two
It is secondary, for the first time 2.5 it is small when, second 2 it is small when, merge alcohol extract, ethanol be recovered under reduced pressure, is concentrated into relative density 1.35 (20
℃)；Radix Salviae Miltiorrhizae add water to cook it is secondary, for the first time 2 it is small when, second 1.5 it is small when, collecting decoction, filtration, filtrate is concentrated into relatively close
Spend 1.35 (20 DEG C)；Above-mentioned two kinds of thick pastes be dry, pulverize into fine powder at 80 DEG C to mix with pseudo-ginseng, banksia rose fine powder.
By the pre-treatment of above-mentioned raw materials medicine, pharmaceutically common preparation can be prepared into, as tablet, capsule, pill,
Granula or oral liquid etc..
Urso is made into 0.6% suspension with distilled water, and ANIT is made into 1% solution with sesame oil.The heart can relax group to
It (is rat with reference to package insert conversion to give compound 1.41g/Kg.d urso groups to give urso 60mg/kg.d
Dosage), Normal group and model group give isometric physiological saline gavage, 4d is used in conjunction in the above.
2. modeling
Normal group, urso group are randomly divided into by table of random number, and the heart can relax group, and model group, each organizes 10
Rat.Sub-cage rearing, fed standard chow, free water, control room temperature (25 ± 2) DEG C, the first adaptability before starting to test
Feed 3d.In addition to Normal group, 1%ANIT sesame oil solutions 50mg/kg was given in the 5th of experiment the day for other 3 groups and once filled
Stomach, the equal fasting for solids but not liquids of all animals of 12h before and after gavage, Normal group then isometric sesame oil gavage.The heart can after 4~6h of modeling
Group, the urso group of relaxing continue to give relative medicine gavage, and model group then still gives isometric physiological saline gavage.Respectively at
24h carries out collection of specimens after modeling.
3. collecting sample
Abdominal aorta is separated after 6% chloraldurate 250mg/kg intraperitoneal injection of anesthesia, extracts 2rnl arterial bloods, 4000r/
Min, 10min.- 20 DEG C of preservations of serum, censorship liver function [total bilirubin (TB), bilirubin direct (DB), phenylalanine ammonia group-transfer
Enzyme (ALT), aspartate aminotransferase (AST), gamma glutamyltransferase (GGT), total bile acid (TBA)].
4. statistical procedures
Statistical analysis is carried out using SPSS13.0 statistical softwares.Measurement data result represents with (x ± s), multigroup to ask
Compare and use one-way analysis of variance, further row Student-Newman-Keuls q inspections in the case of variant
Test.
3rd, result
Each group rat is without death.Normal group：Rat is vibrant, and hair is submissive glossy, and urine color is limpid, hepatic tissue
Surface is ruddy smooth, implements to see that bile smoothly flows out during biliary drainage.Model group：Rat lacks cordiality, and hair is in disorder, loses light
Pool, activity and feed are reduced, and urine color depth is yellow, and hepatic tissue loses ruddy smooth appearance, partly see yellow tubercle, courage during 24h
Juice flow tails off, and dilatation of intestine is obvious, partly sees Poisoning intestinal tympanites.The heart can relax group：Activities in rats and feed are bright compared with model group
Show, urine color is shallow compared with model group, and hepatic tissue yellow tubercle is less, and dilatation of intestine is also light.
Each group Liver function grade situation
1 each group serum liver functional level of table
Note：Compared with normal group,△P<0.05；Compared with model group,*P<0.05。
As known from the above, compared with normal group, model group ALT, AST, TB, DB, GGT, TBA are above normal group of (P<
0.05) modeling success, is illustrated；Compared with model group, can relax group, bear of the heart goes ALT, AST, TB, DB, GGT, TBA of cholic acid group equal
Less than model group (P<0.05), illustrate that they have certain therapeutic effect.
4th, conclusion
The heart, which can relax, has cholestasis good therapeutic effect.
Claims (7)
1. purposes of the composition matched as follows in the medicine for preparing treatment cholestatic hepatitis；The composition is by weighing as follows
The preparation that the bulk pharmaceutical chemicals of amount proportioning are prepared：
375 parts of hawthorn, 375 parts of Radix Salviae Miltiorrhizae, 375 parts of pueraria lobata, 25 parts of pseudo-ginseng, 25 parts of the banksia rose.
2. purposes according to claim 1, it is characterised in that：The medicine is the medicine for treating acute viral cholestatic hepatitis.
3. purposes according to claim 2, it is characterised in that：The medicine is the total of reduction acute viral cholestatic hepatitis patient
Bilirubin (TB), bilirubin direct (DB), alanine aminotransferase (ALT), aspartate aminotransferase (AST), γ-paddy
The medicine of aminoacyl transferases (GGT), total bile acid (TBA).
4. purposes according to claim 1, it is characterised in that：The composition is the medicinal powder or/and raw material with bulk pharmaceutical chemicals
The water or/and ethanol extract of medicine are active ingredient, plus the preparation that pharmaceutically common auxiliary material is prepared.
5. purposes according to claim 4, it is characterised in that：The preparation method of the active ingredient is as follows：Take pseudo-ginseng, wood
Face powder is broken into fine powder；After hawthorn, pueraria lobata add 60% ethanol temperature to soak 30 minutes, heating and refluxing extraction is secondary, when first time 2.5 is small,
Second 2 it is small when, merge alcohol extract, ethanol be recovered under reduced pressure, liquid is concentrated into the medicinal extract for surveying that relative density is 1.35 at 20 DEG C；It is red
Ginseng add water to cook it is secondary, for the first time 2 it is small when, second 1.5 it is small when, collecting decoction, filtration, filtrate be concentrated at 20 DEG C survey it is opposite
Density is 1.35 medicinal extract；Above-mentioned two kinds of thick pastes be dry, pulverize into fine powder at 80 DEG C to mix with pseudo-ginseng, banksia rose fine powder, i.e.,
Obtain active ingredient.
6. according to the purposes described in claim 1 ~ 5 any one, it is characterised in that：The preparation is oral formulations.
7. purposes according to claim 6, it is characterised in that：The oral formulations be tablet, capsule, pill,
Granula or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410628529.8A CN104623005B (en) | 2013-11-08 | 2014-11-07 | The new application that the heart can relax |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310554194 | 2013-11-08 | ||
| CN2013105541945 | 2013-11-08 | ||
| CN201410628529.8A CN104623005B (en) | 2013-11-08 | 2014-11-07 | The new application that the heart can relax |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104623005A CN104623005A (en) | 2015-05-20 |
| CN104623005B true CN104623005B (en) | 2018-05-01 |
Family
ID=53202567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410628529.8A Active CN104623005B (en) | 2013-11-08 | 2014-11-07 | The new application that the heart can relax |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104623005B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109125436A (en) * | 2017-06-28 | 2019-01-04 | 四川科瑞德制药股份有限公司 | The heart can relaxation grain agent preparation method |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006836A (en) * | 2012-12-25 | 2013-04-03 | 泸州百草堂中药饮片有限公司 | Preparation method of drug capable of promoting blood circulation to remove blood stasis and promoting qi circulation to relieve pains |
-
2014
- 2014-11-07 CN CN201410628529.8A patent/CN104623005B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103006836A (en) * | 2012-12-25 | 2013-04-03 | 泸州百草堂中药饮片有限公司 | Preparation method of drug capable of promoting blood circulation to remove blood stasis and promoting qi circulation to relieve pains |
Non-Patent Citations (2)
| Title |
|---|
| 保肝汤在酒精性脂肪肝预防和治疗作用的实验研究;江国荣等;《安徽医药》;20100131;第14卷(第1期);第22-25页 * |
| 活血祛瘀药在治疗淤胆型肝炎中的应用;樊荣强;《光明中医》;20110228;第26卷(第2期);第362-363页 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104623005A (en) | 2015-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102133222A (en) | Compound Chinese medicine extract preventing arteriosclerosis and preparation method thereof | |
| CN103127232A (en) | Total extract for mulberry leaf prescription as well as preparation and usage thereof | |
| CN108404062A (en) | Treat the Chinese medicine composition and its preparation method and application of hyperlipidemia | |
| CN101849979B (en) | Chinese medicinal composition granules and preparation method thereof | |
| CN101496894B (en) | Medicament for treating fatty liver and preparation method thereof | |
| CN103372051B (en) | Red rice and kudzuvine root medicinal composition for regulating blood fat and preparation method of the composition | |
| CN100571761C (en) | A kind of Chinese medicine composition and preparation method for the treatment of hepatopathy | |
| CN103372073A (en) | Red rice and hawthorn medicinal composition for regulating blood fat and preparation method of composition | |
| CN109125315A (en) | Composition and purposes with hypoglycemic, reducing blood lipid and hypotensive activity | |
| CN104623005B (en) | The new application that the heart can relax | |
| CN106535912B (en) | Control pharmaceutical composition and its application of human body blood fat and body weight | |
| CN103191221A (en) | Antiobesity effect of hedan preparation | |
| CN104043042A (en) | Traditional Chinese medicine composition for treating hepatic calculus | |
| CN103550688A (en) | Traditional Chinese medicine (TCM) composition for treating palpitation | |
| CN110237132B (en) | Kidney-tonifying and lipid-lowering medicine, preparation method and application thereof | |
| CN103845477A (en) | Pericarpium citri reticulatae extract with antihyperlipidemic effect and application thereof | |
| CN103372040B (en) | Monas cuspurpureus Went Rhizoma Chuanxiong drug regimen of a kind of adjusting blood lipid and preparation method thereof | |
| CN103272146B (en) | Medicine composition used for preventing and treating alcoholic fatty liver and preparation method thereof | |
| CN105727089A (en) | Application of medicine composition containing folium artemisiae argyi to preparing medicine for treating irritable bowel syndrome | |
| CN103372114B (en) | Red rice and rhizoma alismatis medicinal composition for regulating blood fat and preparation method of composition | |
| CN103355454A (en) | Food health-care tea electuary for preventing osteoporosis | |
| CN105412438B (en) | A kind of for Chinese medicine composition treating coronary heart disease and its preparation method and application | |
| CN107551054A (en) | Sugared numbness washout side composition, its preparation method and its application | |
| CN102138947B (en) | Propolis Chinese medicinal composition | |
| CN105853582A (en) | Folium artemisiae argyi containing medicine preparation for treating cholelithiasis and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190402 Address after: 110 000 No. 12 Central Avenue, Dongdaying Industrial Park, Shenyang City, Liaoning Province Patentee after: Shenyang Kangda Pharmaceutical Group Co., Ltd. Address before: 610000 Room 206, Building 5, Gaopeng Avenue, Chengdu High-tech Zone, Sichuan Province Patentee before: Chengdu Baicao Heji Technology Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 110 000 No. 12 Central Avenue, Dongdaying Industrial Park, Shenyang City, Liaoning Province Patentee after: Shenyang Qinggong Pharmaceutical Group Co., Ltd. Address before: 110 000 No. 12 Central Avenue, Dongdaying Industrial Park, Shenyang City, Liaoning Province Patentee before: Shenyang Kangda Pharmaceutical Group Co., Ltd. |